About the report
In partnership with Citeline, we present an overview of recent developments from one of Europe’s most exciting life science innovation clusters, the Medicon Valley.
The Medicon Valley has the second highest number of manufacturing facilities in Europe and the highest number of contract development and manufacturing organization (CDMO) facilities. Recently, there has been considerable international and local investment in CDMOs. FujiFilm Diosynth Biotechnologies’ facility is undergoing a multibillion-dollar expansion and AGC Biologics’ Copenhagen site has doubled the size of its single-use bioreactor capacity for mammalian services with a $239M investment.
Incubators in the region continue to successfully support early-stage research, spin-outs and start-ups within life sciences. Partnerships have been established with big pharma to provide coaching, workspace, and capital injection, while graduate companies elevate capital investment through larger fundraising, including IPOs, licenses and M&As. SmiLe’s CEO, Ebba Fåhraeus was recently appointed a member of the Swedish government’s life science advisory group and provides guidance and strategies to elevate life science innovation.
The Medicon Valley biopharma industry is attracting substantial investment from local and international investors. From July 2023 to June 2024 companies in the Medicon Valley secured considerably more than any other life science cluster in Europe with $3B in financing. What’s more, the number of drugs in active development in the region is at an all-time high and the number of European biopharma companies headquartered here is second, behind only London.